| Issue |
Parasite
Volume 25, 2018
|
|
|---|---|---|
| Article Number | 33 | |
| Number of page(s) | 2 | |
| DOI | https://doi.org/10.1051/parasite/2018039 | |
| Published online | 16 July 2018 | |
Short Note
High-dose ivermectin in malaria and other parasitic diseases: a new step in the development of a neglected drug
Ivermectine à forte dose dans le paludisme et d’autres maladies parasitaires: une nouvelle étape dans le développement d’un médicament négligé
1
Department of Dermatology, Hôpital Henri-Mondor, AP–HP, Créteil, France
2
Research group EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques) EA 7379, Université Paris-Est Créteil Val-de-Marne, Créteil, France
3
French Satellite of the Cochrane Skin Group, Créteil, France
4
Research Group Dynamyc, EA7380, Ecole nationale vétérinaire d’Alfort, Maisons-Alfort, Université Paris-Est Créteil, Créteil, France
5
Department of Internal Medicine, Centre Hospitalier Intercommunal de Créteil, Créteil, France
* Corresponding author: olivier.chosidow@aphp.fr
Received:
3
June
2018
Accepted:
25
June
2018
We highlight the absence of high-level evidence from dose-ranging studies regarding the use of oral ivermectin in susceptible parasitic diseases. We provide published data supporting the use of a higher dosage regimen of ivermectin in malaria and difficult-to-treat head lice, and announce an ongoing randomized clinical trial in severe scabies.
Résumé
Nous soulignons l’absence de données probantes de haut niveau sur les études de dosage concernant l’utilisation de l’ivermectine par voie orale dans les maladies parasitaires sensibles. Nous fournissons des données publiées soutenant l’utilisation d’un régime plus élevé d’ivermectine dans le paludisme et les poux de tête difficiles à traiter, et nous annonçons un essai clinique randomisé en cours dans la gale sévère.
Key words: Oral ivermectin / High doses / Malaria / Head lice / Scabies
Member of the steering committee of IACS (International Alliance for the Control of Scabies) (www.controlscabies.org)
© O. Chosidow et al., published by EDP Sciences, 2018
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.